How to Help Your Patients Save Money on Insulin, Human Isophane (NPH): A Provider's Guide to Savings Programs

Insulin affordability is a critical issue in diabetes management. Without assistance, NPH insulin (Humulin N or Novolin N) can cost $148-158 per vial at retail — a burden that leads many patients to ration doses or skip refills, with potentially life-threatening consequences. This guide is designed for prescribers and care teams to equip you with the programs and resources to help your patients access affordable NPH insulin in 2026.

Why Insulin Affordability Affects Clinical Outcomes

Research consistently shows that patients who struggle to afford insulin ration doses, skip injections, or delay refills — all of which worsen glycemic control and increase the risk of hospitalizations, emergency department visits, and diabetes-related complications. For Type 1 patients especially, a missed insulin dose is never simply a missed dose — it can trigger diabetic ketoacidosis within hours.

Proactively screening patients for cost barriers and connecting them to savings programs before problems arise is one of the highest-value interventions a prescriber can make.

The $25 OTC Option: Walmart ReliOn Novolin N

The most underutilized savings option for uninsured patients on NPH insulin is one of the simplest: Walmart's ReliOn Novolin N. This is the same medication as Novolin N — insulin isophane human, 100 units/mL — sold at Walmart pharmacies for approximately $25 per 10 mL vial without a prescription.

Clinical considerations when directing patients to the Walmart OTC option:

• Pharmacologically identical to Novolin N; the same prescribing considerations apply.
• Patient should still receive education on dose measurement, injection technique, and hypoglycemia recognition — the purchase being OTC does not mean the patient is clinically supervised.
• Maintain your prescription on record so there is no gap in oversight, even when the patient fills OTC.

Manufacturer Savings Programs

Both major NPH insulin manufacturers offer robust savings programs your patients can access:

• Lilly Insulin Value Program (Humulin N): Cap of $35/month for any number of vials or pens. No income requirement. Works for commercially insured, uninsured, and Medicare patients (though Medicare patients already have the IRA cap). Registration at insulinaffordability.com or call 1-833-808-1234. Valid through 12/31/2026.
• Novo Nordisk My Insulin Rx (Novolin N): $35 per fill for up to 3 vials, 2 packs of pens, or any combination up to 35 mL. No insurance required. Patients register at novocare.com or call 1-888-910-0632.

Patient Assistance Programs (Free Insulin)

For patients who are uninsured and have limited income, both manufacturers offer patient assistance programs that provide NPH insulin at no cost:

• Lilly Cares Foundation (Humulin N): Free insulin for uninsured patients with limited income. Authorization is effective for one year and is renewable. Your office will need to complete the application available at lillycares.com. Applications can be submitted by mail or fax. Call 1-800-545-6962 for assistance.
• Novo Nordisk Patient Assistance Program (Novolin N): Free Novolin N for patients without insurance with limited income. Requires valid prescription and proof of household income. Call 1-866-310-7549 or visit novocare.com/psp/PAP.html.

Medicare Patients: The IRA $35/Month Insulin Cap

As of January 2024, the Inflation Reduction Act permanently capped Medicare Part D beneficiaries' out-of-pocket cost for covered insulin products at $35/month. This applies to all Medicare Part D plans and covers both Humulin N and Novolin N. There are no deductibles or other out-of-pocket costs for insulin under this provision.

Action for your practice: Verify that all Medicare patients on NPH insulin are aware of the $35 cap and that their pharmacy is applying it correctly. If a patient reports paying more than $35/month, ask them to contact their Part D plan or the Medicare helpline (1-800-MEDICARE).

State Insulin Affordability Laws

Over 20 states have passed their own insulin affordability legislation, with copay caps ranging from $25 to $100 per month for commercially insured patients. Some states also have emergency supply programs. Encourage patients to check their state's pharmacy board or health department website, or use NeedyMeds.org to search for state-specific programs.

Quick Reference: Decision Tree for Prescribers

1. Uninsured, any income: Start with Walmart ReliOn Novolin N (~$25/vial OTC). Also register for Lilly or Novo Nordisk $35/month programs.
2. Uninsured, limited income: Apply for Lilly Cares Foundation or Novo Nordisk PAP for free insulin.
3. Commercially insured: Lilly Insulin Value Program caps Humulin N at $35/month. Check state copay cap laws as well.
4. Medicare Part D: $35/month cap under IRA. Verify the cap is being applied at the pharmacy.

When patients are struggling to both find and afford their NPH insulin, medfinder helps by locating which pharmacies near them have the medication in stock. Directing patients to medfinder.com reduces the burden on your office and helps patients get their medication faster.